PAT Rs 147.90 Crore | Syngene International Q4 FY26 Results

Syngene International announced its Q4 FY26 financial results on April 29, 2026, reporting PAT of Rs 147.90 crore, a 19.3 percent year-on-year decline, as the Contract Research and CDMO company delivered its January to March 2026 quarter earnings. Syngene International Q4 FY26 results are closely tracked by investors as a key indicator of the company’s performance trajectory. This article covers the Syngene International Q4 FY26 financial highlights, performance analysis, full year FY26 summary, management outlook, and frequently asked questions on Syngene International Q4 results.

Syngene International Q4 FY26 Financial Highlights

Syngene International reported Q4 FY26 consolidated PAT of Rs 147.90 crore (after exceptional items), a 19.3 percent year-on-year decline from Rs 183.30 crore in Q4 FY25. Q4 FY26 revenue was Rs 1,037 crore. EBITDA margin stood at 30.8 percent. The company completed 14 audits in Q4 and received GCP-NABL accreditation. Kiran Mazumdar-Shaw transitioned to Executive Chairperson from April 2026. Siddharth Mittal appointed as MD and CEO from July 2026.

Metric	Q4 FY26	Q4 FY25	YoY Change
Revenue / Total Income	Rs 1,037 crore	Refer NSE/BSE filing	Grew YoY
PAT	Rs 147.90 crore	Refer NSE/BSE filing	Lower 19.3 percent YoY
Full Year FY26 PAT	Refer annual filing	Refer filing	As reported
Dividend (FY26)	Not declared	Refer filing	FY26 final

Also Read: Bhansali Engineering Polymers Q4 FY26 Results

Syngene International Q4 FY26 Performance Analysis

Syngene International Q4 FY26 PAT decline of 19.3 percent reflects the company’s continued heavy investment in biologics, ADC (Antibody-Drug Conjugate), and CDMO capacity expansion, which has increased depreciation and amortisation costs. The company completed 85 regulatory audits for FY26 and was included in the S and P Global Sustainability Yearbook 2026 top 10 life sciences companies.

Syngene International Q4 FY26 EBITDA margin at 30.8 percent remained healthy despite investment headwinds. Revenue grew modestly as new biologics and ADC CDMO capacities at the Mangaluru facility begin ramping up.

Syngene International Full Year FY26 Business Summary

For FY26, Syngene reported revenue of Rs 3,738.7 crore (up 2.6 percent YoY) and EBITDA of Rs 989.1 crore (down 11.2 percent) with margin at 26 percent versus 30 percent in FY25. Biologics and ADC infrastructure investments are the primary reason for margin compression.

Syngene International Q4 FY26 Outlook and FY27 Priorities

Syngene International FY27 outlook is positive as biologics and ADC capacities ramp up under new CEO Siddharth Mittal. Recovery in global biopharma outsourcing demand and Syngene’s expanded capabilities set up stronger FY27 revenue growth.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces!

Conclusion

The Syngene International Q4 FY26 results provide investors with the company’s January to March 2026 performance data. Syngene International Q4 FY26 PAT of Rs 147.90 crore reflects the operational performance in the Contract Research and CDMO sector. Investors tracking Syngene International Q4 results should review the complete audited financials on NSE and BSE exchange filings before making any investment decision. Syngene International Q4 FY26 is an important milestone in the company’s annual earnings calendar.

This article on Syngene International Q4 FY26 results is for informational and educational purposes only. It is not investment advice. Please consult a SEBI registered investment advisor before making any investment decision. Past performance is not indicative of future results.

Frequently Asked Questions on Syngene International Q4 FY26 Results

What were the Syngene International Q4 FY26 results?

Syngene International Q4 FY26 results were announced on April 29, 2026. The company reported PAT of Rs 147.90 crore for the January to March 2026 quarter. Syngene International Q4 FY26 details are in the official NSE and BSE exchange filings.

What was Syngene International Q4 FY26 PAT?

Syngene International Q4 FY26 PAT was Rs 147.90 crore, lower 19.3 percent YoY. The Syngene International Q4 FY26 results were announced on April 29, 2026, at the board of directors meeting to approve audited financials.

What was Syngene International Q4 FY26 revenue?

Syngene International Q4 FY26 revenue was Rs 1,037 crore. Investors should refer to the NSE and BSE exchange filing for the full audited Syngene International Q4 FY26 revenue breakdown and segmental performance data.

Did Syngene International declare a dividend after Q4 FY26 results?

Syngene International did not declare a dividend in the Q4 FY26 results announcement. Refer to the official exchange filing for confirmation.

What is the outlook for Syngene International after Q4 FY26?

Syngene International FY27 outlook is positive as biologics and ADC capacities ramp up under new CEO Siddharth Mittal. Recovery in global biopharma outsourcing demand and Syngene’s expanded capabilities set up stronger FY27 revenue growth. Investors should monitor management commentary and quarterly filings for updated guidance on Syngene International Q4 FY26 performance sustainability into FY27.

How did Syngene International Q4 FY26 compare year on year?

Syngene International Q4 FY26 PAT of Rs 147.90 crore was lower 19.3 percent YoY. The year-on-year comparison for Syngene International Q4 FY26 versus Q4 FY25 is available in the official audited NSE and BSE exchange filings.

What sector does Syngene International operate in?

Syngene International operates in the Contract Research and CDMO sector in India and is listed on NSE and BSE. Syngene International Q4 FY26 results reflect the broader Contract Research and CDMO sector trends for the January to March 2026 quarter. Contextualising Syngene International Q4 performance within industry dynamics requires reviewing sector-level data alongside management commentary.

Is Syngene International a good investment after Q4 FY26 results?

Whether Syngene International is a good investment after the Syngene International Q4 FY26 results depends on your individual financial goals, risk tolerance, and investment horizon. Syngene International Q4 FY26 results provide one data point on the company’s trajectory. Always consult a SEBI registered financial advisor before making any investment decision.

Recent Article

Torrent Power Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Usha Martin Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Triveni Engineering and Industries Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Utkarsh Small Finance Bank Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Venus Pipes and Tubes Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook